As drug discovery moves from trial-and-error to digital simulation, choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrödinger (NASDAQ:SDGR) depends on ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

A new frontier AI company called Recursive Superintelligence has emerged from stealth with $650 million in funding and an unusually ambitious goal: building AI systems capable of improving themselves ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Najat Khan looks at successful platform companies like Vertex, Regeneron and Alnylam and sees a path for Recursion to join them—if the company stays disciplined. (Recursion Pharmaceuticals) Chris ...

JDK 26 moves to general production availability. This short-term release is backed by six months of Premier-level support. Java Development Kit (JDK) 26, the latest standard Java release from Oracle, ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...